Ruffolo R R, Waddell J E
J Pharmacol Exp Ther. 1982 Jul;222(1):29-36.
The alpha-1 and alpha-2 adrenergic effects of cirazoline were evaluated in guinea-pig aorta and field-stimulated guinea-pig ileum, respectively. Cirazoline was found to be a full agonist at alpha-1 receptors having an ED50, dissociation constant (KA) and relative efficacy similar to that of (-)-norepinephrine. In contrast, cirazoline does not possess agonist activity at presynaptic alpha-2 receptors in the guinea-pig ileum. Thus, whereas norepinephrine and cirazoline both inhibited the twitch response of the field-stimulated ileum, only the response to norepinephrine was blocked by the selective alpha-2 antagonist, yohimbine. The nonadrenergic inhibition of the twitch response observed in the ileum with cirazoline resulted from weak anticholinergic activity (antimuscarinic) at the level of the postsynaptic effector organ and was observed only at high concentrations. At concentrations far below the level required to inhibit the twitch response, cirazoline was found to competitively antagonize the alpha-2-mediated inhibition of the twitch response elicited by norepinephrine. A Schild plot analysis indicated that cirazoline is a potent competitive alpha-2 receptor antagonist characterized by a pA2 value (i.e., -log KB) of 7.56. These results indicate that cirazoline is unique among imidazolines in that it is a potent alpha-1 adrenergic receptor agonist and an even more potent alpha-2 receptor antagonist. This unusual combination of activities could make cirazoline a particularly effective vasoconstricting agent.
分别在豚鼠主动脉和电刺激的豚鼠回肠中评估了西拉唑啉的α-1和α-2肾上腺素能效应。发现西拉唑啉是α-1受体的完全激动剂,其半数有效量(ED50)、解离常数(KA)和相对效能与(-)-去甲肾上腺素相似。相比之下,西拉唑啉在豚鼠回肠的突触前α-2受体上不具有激动剂活性。因此,虽然去甲肾上腺素和西拉唑啉都抑制了电刺激回肠的抽搐反应,但只有对去甲肾上腺素的反应被选择性α-2拮抗剂育亨宾阻断。西拉唑啉在回肠中观察到的对抽搐反应的非肾上腺素能抑制是由突触后效应器官水平的弱抗胆碱能活性(抗毒蕈碱)引起的,并且仅在高浓度时观察到。在远低于抑制抽搐反应所需浓度的情况下,发现西拉唑啉竞争性拮抗去甲肾上腺素引起的α-2介导的抽搐反应抑制。Schild图分析表明,西拉唑啉是一种有效的竞争性α-2受体拮抗剂,其pA2值(即-log KB)为7.56。这些结果表明,西拉唑啉在咪唑啉类药物中是独特的,因为它是一种有效的α-1肾上腺素能受体激动剂,更是一种有效的α-2受体拮抗剂。这种不寻常的活性组合可能使西拉唑啉成为一种特别有效的血管收缩剂。